Prostate Health Index (phi)
The Prostate Health Index (phi) is a calculation that uses a combination of three blood tests to produce a "phi score." This score provides more information about what elevated PSA levels might mean and the probability of finding prostate cancer on biopsy.*
Brochure The phi Clinical Summary
The superior performance of phi compared to PSA alone has been demonstrated through multiple peer-reviewed publications. Read summaries of the articles and discover the power of phi.Download
1Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol, 2015; 193(4):1163-9.
2Jay White B, Vittal Shenoy, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-017-0008-7.
3Beckman Coulter Access Hybritech p2PSA Instructions for Use.
*phi results are intended to be used as an aid in distinguishing prostate cancer from benign prostatic conditions in men 50 years of age and older with total PSA results in the 4-10 ng/mL range and negative digital rectal examination DRE findings.
†Biopsy outcomes of patients in the 4-10 ng/mL range.
‡Indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions in men aged 50 years and older with total PSA results in the 4-10 ng/mL in the U.S and or the 2-10 ng/mL range outside the U.S.